Home » Newsletters » BioWorld Science

BioWorld Science

July 11, 2007

View Archived Issues

Summary of studies evaluating the effect of various natural products on diabetes

Profile of the antithrombotic agent rivaroxaban

Preclinical studies characterize the antithrombotic effect of MCC-977

Rapid, high-level platelet inhibition seen with PRT-060128 in humans

Antithrombotic activity seen with TGX-221 in vivo

Withaferin A holds promise as a potential drug lead

Alkaline phosphatase shows promise in ulcerative colitis

Peregrine acquires rights to antiangiogenesis technology from M.D. Anderson

ADL-5859 begins phase II pain study

Enrollment completed in phase II cardiovascular restenosis trial of Resten-MP

GRN-163L begins phase I/II study in advanced NSCLC

Biologics Menoflavon launched in Canada

Recent patents disclose novel antiinfective agents

DSM and Crucell sign licensing agreement with Masterclone to develop antibody

NPS and Nycomed expand Preotact agreement

Update on Karo Bio and Merck collaboration

CV Therapeutics identifies potential first-in-class MOA for ranolazine

Gilead initiates expanded access program for aztreonam lysine for CF

CB-7630 shows activity in prostate cancer trials

Nimotuzumab shown to bind to EGF receptor and potentiate radiotherapy

U.S. orphan drug designation for Corlux in Cushing's syndrome

New agents for gastrointestinal disorders described in recent patents

Zybrestat begins pivotal study in anaplastic thyroid cancer

Novel analgesic agents imparted in recent patent literature

NV-1020 shows promise in metastatic colorectal cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...